Alnylam Pharmaceuticals (NASDAQ:ALNY) Given New $325.00 Price Target at Chardan Capital

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) had its price objective raised by research analysts at Chardan Capital from $300.00 to $325.00 in a research note issued to investors on Friday,Benzinga reports. The firm currently has a "buy" rating on the biopharmaceutical company's stock. Chardan Capital's price objective suggests a potential upside of 18.81% from the company's previous close.

Other equities research analysts have also recently issued research reports about the stock. Stifel Nicolaus increased their price target on shares of Alnylam Pharmaceuticals from $300.00 to $345.00 and gave the company a "buy" rating in a research report on Monday, March 31st. Wells Fargo & Company increased their target price on shares of Alnylam Pharmaceuticals from $275.00 to $287.00 and gave the stock an "equal weight" rating in a report on Friday, March 21st. JPMorgan Chase & Co. upgraded Alnylam Pharmaceuticals from a "neutral" rating to an "overweight" rating and boosted their price target for the company from $280.00 to $328.00 in a report on Monday, March 24th. Needham & Company LLC reaffirmed a "buy" rating and set a $320.00 price target on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 9th. Finally, HC Wainwright reiterated a "buy" rating and issued a $500.00 price objective on shares of Alnylam Pharmaceuticals in a research report on Wednesday, April 2nd. One analyst has rated the stock with a sell rating, five have assigned a hold rating and twenty-one have assigned a buy rating to the company. According to MarketBeat, Alnylam Pharmaceuticals presently has an average rating of "Moderate Buy" and an average target price of $319.17.

Alnylam Pharmaceuticals Trading Up 5.5 %

Shares of Alnylam Pharmaceuticals stock traded up $14.16 during trading on Friday, reaching $273.55. The company's stock had a trading volume of 1,233,402 shares, compared to its average volume of 888,234. The company has a quick ratio of 2.71, a current ratio of 2.78 and a debt-to-equity ratio of 15.27. Alnylam Pharmaceuticals has a 52-week low of $144.73 and a 52-week high of $304.39. The firm's 50-day moving average is $248.81 and its two-hundred day moving average is $254.55. The company has a market cap of $35.58 billion, a price-to-earnings ratio of -126.06 and a beta of 0.17.

Alnylam Pharmaceuticals (NASDAQ:ALNY - Get Free Report) last issued its earnings results on Thursday, May 1st. The biopharmaceutical company reported ($0.44) earnings per share for the quarter, missing the consensus estimate of ($0.37) by ($0.07). The company had revenue of $594.19 million during the quarter, compared to the consensus estimate of $584.32 million. Alnylam Pharmaceuticals's revenue for the quarter was up 20.2% compared to the same quarter last year. During the same period in the previous year, the company earned ($0.16) EPS. On average, sell-side analysts anticipate that Alnylam Pharmaceuticals will post -1.7 earnings per share for the current year.

Insider Activity at Alnylam Pharmaceuticals

In other Alnylam Pharmaceuticals news, CFO Jeffrey V. Poulton sold 967 shares of the business's stock in a transaction on Friday, February 14th. The shares were sold at an average price of $255.17, for a total transaction of $246,749.39. Following the completion of the sale, the chief financial officer now directly owns 32,786 shares in the company, valued at approximately $8,366,003.62. The trade was a 2.86 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, EVP Kevin Joseph Fitzgerald sold 663 shares of Alnylam Pharmaceuticals stock in a transaction on Friday, February 14th. The stock was sold at an average price of $255.21, for a total value of $169,204.23. Following the completion of the sale, the executive vice president now directly owns 14,321 shares of the company's stock, valued at $3,654,862.41. The trade was a 4.42 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders have sold 7,392 shares of company stock valued at $1,875,627. 1.50% of the stock is owned by corporate insiders.

Hedge Funds Weigh In On Alnylam Pharmaceuticals

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Whipplewood Advisors LLC lifted its position in Alnylam Pharmaceuticals by 208.8% during the first quarter. Whipplewood Advisors LLC now owns 105 shares of the biopharmaceutical company's stock valued at $28,000 after purchasing an additional 71 shares in the last quarter. Bessemer Group Inc. lifted its stake in Alnylam Pharmaceuticals by 176.9% in the 1st quarter. Bessemer Group Inc. now owns 108 shares of the biopharmaceutical company's stock worth $29,000 after purchasing an additional 69 shares in the last quarter. Larson Financial Group LLC lifted its position in shares of Alnylam Pharmaceuticals by 187.2% in the fourth quarter. Larson Financial Group LLC now owns 112 shares of the biopharmaceutical company's stock worth $26,000 after buying an additional 73 shares in the last quarter. Park Square Financial Group LLC bought a new stake in Alnylam Pharmaceuticals in the 4th quarter worth approximately $28,000. Finally, R Squared Ltd purchased a new position in shares of Alnylam Pharmaceuticals in the fourth quarter valued at $33,000. Hedge funds and other institutional investors own 92.97% of the company's stock.

About Alnylam Pharmaceuticals

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.